Search Go
Follow Us:  linkedin twitter slideshare youtube google + pinterest
 

Benchmark Studies

The benchmark studies below are part of Best Practices, LLC's ongoing Research and Consulting initiatives. By participating in one of the following surveys, you will receive a free copy of the results in presentation format. All benchmark study results are blinded and aggregated to ensure confidentiality.

You can access free excerpts of previous studies archived under
Benchmarking Reports and Best Practice Database.

Current Benchmark Studies Subscribe to our RSS Feed of Current Surveys

  • Developing World-Class Regulatory Systems That Lead to Successful NDAs and Optimize FDA Working Relationships
  • Survey Topic: Developing World-Class Regulatory Systems That Lead to Successful NDAs and Optimize FDA Working Relationships

    Objective: Bringing New Drug Applications (NDA) through the Food and Drug Administration (FDA) approval process is the gateway to commercial success. However, increasing safety concerns, market and political pressures, make this NDA approval process more difficult than ever.

    Those companies that develop effective systems to work with the FDA enjoy a critical advantage in the commercialization process.

    This biopharmaceutical benchmarking study is designed to gain insights into how pharmaceutical companies successfully interact with employees of the Food and Drug Administration during the NDA process.


    Lead Researcher: Cameron Tew

    Invited Participants: Executives that oversee, manage and direct functions that interact with the Food and Drug Administration during the New Drug Application process.

    Participate in this SurveyShare this Survey: Email LinkedIn Twitter

    Contact: If you have questions about the survey or require assistance, please contact Cameron Tew at (919)-767-9246 or ctew@best-in-class.com.  


  • Thought Leader Fair Market Value - 2016
  • Survey Topic: Thought Leader Fair Market Value - 2016


    Objective: With increasing importance of transparency, healthcare leaders must provide a clear line of sight into how they compensate industry thought leaders and physicians. Bio-pharma executives are being pressed to re-assess their current thought leader compensation strategies as new state reporting laws and changes to their organizations’ policies (PhRMA code, ACCME guidelines, etc.) are being enforced. At the same time, access to thought leaders themselves has continued to shrink, whether in academic institutions or elsewhere.

    Put simply, it has never been more important for healthcare companies to get it right when it comes to thought leader management. This benchmarking study is designed to examine trends in Fair Market Value for thought leaders, capturing critical metrics and insights on thought leader management, compensation levels, and proven practices.

    Lead Researcher: Cameron Tew

    Invited Participants: Vice presidents, executives, directors, managers, and other professionals working within Medical Affairs and thought leader management functions.

    Time Commitment: Approximately Time25-30 minutes

    Participate in this SurveyShare this Survey: Email LinkedIn Twitter

    Contact: If you have questions about the survey or require assistance, please contact Cameron Tew at (919)-767-9246 or ctew@best-in-class.com.  


  • NEW 2016 - Winning the Necessary Resources for a Successful Product Launch
  • Survey Topic: NEW 2016 - Winning the Necessary Resources for a Successful Product Launch


    Objective: Pharmaceutical companies can no longer afford to rely solely on past experience when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study investigates current costs as well as budget and staffing allocations required for a successful drug launch.Pharmaceutical leaders who participate in this study can use the resulting benchmark data to determine whether their own investment levels for promotional, educational, market access, Medical Affairs, and other launch-related activities are competitive in the new marketplace.

    Lead Researcher: Cameron Tew

    Invited Participants: Pharma and biotech executives, directors, managers, and brand team leaders who have recent or current experience with the launch (or launch preparation) of a new pharmaceutical product.


    Participate in this SurveyShare this Survey: Email LinkedIn Twitter


    Contact: If you have questions about the survey or require assistance, please contact Cameron Tew, Head of Research, at (919)-767-9246 or ctew@best-in-class.com.  


  • 2016 Digital Marketing Benchmarks: Building Top-Tier Biopharma Digital Strategy, Services & Operations
  • Survey Topic: 2016 Digital Marketing Benchmarks: Building Top-Tier Biopharma Digital Strategy, Services & Operations


    Objective: Elite healthcare organizations are investing more than ever in digital marketing to learn about their customers, build better relationships, and leverage effect online media at lower costs.

    This study will establish new benchmarks and provide critical insights into how savvy biopharma digital marketers are using new tools and tactics to educate key customers, enhance reach, boost speed, raise sales force effectiveness, measure and increase customer satisfaction, and help offset declining HCP access.

    Participants in this survey will be able to benchmark themselves against leading biopharma and medical device organizations in the following areas: Digital strategy, launch excellence, staffing & investment, performance & ROI measurement, analytics, service alignment, field sales support, mobile engagement, social media, electronic health records, digital health & innovation, compliance & risk mitigation, outsourcing, and cost management.


    Lead Researcher: James Drake

    Invited Participants: Executives, directors, managers or staff specialists who are knowledgeable about their company's digital and multichannel marketing functions or activities.

    Time Commitment: Approximately Time20-30 minutes

    Participate in this SurveyShare this Survey: Email LinkedIn Twitter


    Contact: If you have questions about participation in this survey or require assistance, please contact James Drake at (603)-410-3929 or jdrake@best-in-class.com.  


  • 2015-2016 Medical Affairs Consortium Survey Part-II: Medical Affairs' Role in Payer Interactions in an Evolving Healthcare Landscape
  • Survey Topic: 2015-2016 Medical Affairs Consortium Survey Part-II: Medical Affairs' Role in Payer Interactions in an Evolving Healthcare Landscape


    Objective: As the need to decrease healthcare costs intensifies, and the number of expensive therapeutics entering the market grows, importance of effective communication with payers became invaluable. Many medical affairs organizations face challenges in planning and management of the rising impact of payers and market access activities.

    This survey seeks to inform Medical Affairs leaders about current industry trends, and to identify benchmarks and best practices in:

    • Market access activities
    • Medical Affairs' role in building and developing strong relationships with payers
    • Payer landscape assessment
    • Talent acquisition and management to communicate effectively with payers
    • Knowledge sharing to avoid redundancies in payer relationships

    Lead Researcher: Ozge Uyanik

    Invited Participants: Managers and executives who lead or work within global or regional Medical Affairs organizations at biopharmaceutical or medical device companies.

    Confidentiality: Survey data will be blinded and aggregated. No data received will be associated with any participating company or individual.

    Deadline: October 23, 2015

    Participate in this SurveyShare this Survey:Email LinkedIn Twitter

    Contact: If you have questions about the survey or require assistance, please contact Ozge Uyanik at (919)-767-9174 or ouyanik@best-in-class.com.  


  • Marketing Orphan Compounds
  • Survey Topic: Marketing Orphan Compounds

    Objective: Orphan drugs are developed for rare diseases that affect five people or fewer in 10,000. Despite its small patient pool,the R&D advances and regulatory incentives have positively impacted the market for orphan drugs. This has encouraged companies to investigate the revenue potential in these drugs that address unmet medical needs. This study is intended to explore strategy and metrics for developing and marketing of orphan drugs.

    Lead Researcher: Cameron Tew


    Participate in this SurveyShare this Survey: Email LinkedIn Twitter

    Contact: If you have questions about the survey or require assistance, please contact Cameron Tew at (919) 767-9246 or ctew@best-in-class.com.



    Benchmark Studies


    Contact Info CONTACT PERSON
    -----------------------------------------

    Jeff Zimmer,
    Senior Research Consultant

    Phone: (919) 767-9180

    Email Email Jeff


     
    ACCESS AND INTELLIGENCE FOR ACHIEVING WORLD-CLASS EXCELLENCE
    Quick Links  Product RSS Feed
    Payment gateway
    Secured by PayPal

    Follow Us: 

    linkedin twitter slideshare youtube google + pinterest

    All contents copyright 1998-2020 Best Practices, LLC (919) 403-0251
    Read our Terms and Conditions of Use, Privacy Policy and Copyright Information